Long-term effects of primary diagnosed hodgkin’s lymphoma therapy in children and adolescents (literature review)

Cover Page

Cite item

Full Text

Abstract

Modern risk-adapted therapy for Hodgkin lymphoma makes it possible to achieve complete remission and sustained long-term event-free survival in the overwhelming majority of patients. However, the problem of developing late treatment-related complications remains relevant. These include secondary malignant neoplasms, cardiovascular and endocrine diseases, reproductive dysfunction, among others.
This article presents a review of the literature on the most frequently occurring late complications of therapy for newly diagnosed classical Hodgkin lymphoma in children, adolescents, and young adults. The need for their early diagnosis and long-term medical follow-up is substantiated. The expediency of developing a strategy to reduce the risk of these complications is determined, which, along with the high effectiveness of antitumor treatment, will make it possible to improve long-term prognosis and quality of life.

About the authors

A. A. Kosova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

M. I. Savelyeva

Yaroslavl State Medical University, Ministry of Health of Russia

5 Revolutsionnaya St., Yaroslavl 150000

Russian Federation

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

P. A. Zeynalova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Bld. 2, 8 Trubetskaya St., Moscow 119991

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

References

  1. Botezatu I.V., Valiev T.T., Dushenkina T.E. et al. Epstein–Barr virus in children with classical Hodgkinʼs lymphoma. Sovremennaya onkologiya = Journal of Modern Oncology 2018;20(1):23–8. (In Russ.).
  2. Baryshnikov A.Yu., Valiev T.T., Gubin A.N. et al. Lymphomas in children. Practical guide. Ed. by G.L. Mantevich, S.A. Mayakova. Moscow: Prakticheskaya meditsina, 2014. 238 p. (In Russ.).
  3. Лимфома Ходжкина. Клинические рекомендации. 2021. Доступно по: https://oncology-association.ru/wp-content/uploads/2021/03/limfoma-hodzhkina-2021.pdf?ysclid=m200zozkho76497668
  4. Hodgkinʼs Lymphoma. Clinical Guidelines. 2021. Available at: https://oncology-association.ru/wp-content/uploads/2021/03/limfoma-hodzhkina-2021.pdf?ysclid=m200zozkho76497668 (In Russ.).
  5. Demina E.A., Tumyan G.S., Moiseeva T.N. et al. Hodgkinʼs lymphoma. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(2):6–33. (In Russ.). doi: 10.26442/18151434.2020.2.200132
  6. Belyaeva E.S., Susuleva N.A., Valiev T.T. The importance of intensive chemotherapy for the treatment of children with advanced stages of Hodgkinʼs lymphoma. RMJ. Mat i ditya = Russian Medical Journal. Mother and Child 2020;3(2):149–54. (In Russ.). doi: 10.32364/2618-8430-2020-3-2-149-154
  7. Huynh-Le M.P., Walker A.J., Kominers S.D. et al. Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin Lymphoma. Pediatr Blood Cancer 2014;61(7):1210–4. doi: 10.1002/pbc.24968
  8. Oeffinger K.C., Stratton K.L., Hudson M.M. et.al. Impact of riskadapted therapy for pediatric Hodgkin lymphoma on risk of longterm morbidity: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2021;39(20):2266–75. doi: 10.1200/JCO.20.01186
  9. Zaeva G.E., Valiev T.T., Gavrilenko T.F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Sovremannaya onkologiya = Journal of Modern Oncology 2016;18(1):55–60. (In Russ.).
  10. Pavlova T.Y., Valiev T.T. Second malignant tumors in pediatric cancer survivors. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum 2020;2:12–6. (In Russ.).
  11. Kuleva S.A., Kurochkina D.N., Zvyagintseva D.A. et al. Oncofertility in men cured of Hodgkin lymphoma in childhood. Meditsinsky sovet = Medical Council 2019;10:164–70. (In Russ.).
  12. Chow E.J., Stratton K.L., Leisenring W.M. et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood
  13. Cancer Survivor Study cohort. Lancet Oncol 2016;17(5):567–76. doi: 10.1016/S1470-2045(16)00086-3
  14. Vinokurov A.A., Varfolomeeva S.R., Tarusin D.I. et al. Fertility of adolescents and young men cured of Hodgkinʼs lymphoma. Zlokachestvenniya opuckholy = Malignant Tumors 2012;2(1):18–28. (In Russ.). doi: 10.18027/2224-5057-2012-1-18-28
  15. Goossens E., Jahnukainen K., Mitchell R.T. et al. Fertility preservation in boys: recent developments and new insights. Hum Reprod Open 2020(3):hoaa016. doi: 10.1093/hropen/hoaa016
  16. Rueffer U., Breuer K., Josting A. et al. Male gonadal dysfunction in patients with Hodgkinʼs disease prior to treatment. Ann Oncol 2001;12(9):1307–11. doi: 10.1023/a:1012464703805
  17. Polyakova M.V. Cryopreservation of spermatogonial stem cells: clinical applications for preserving fertility in prepubertal patients.
  18. Zhurnal mediko-biologicheskih issledovaniy = Journal of Medical and Biological Research 2017;5(3):33–42. doi: 10.17238/issn2542-1298.2017.5.3.33
  19. Meirow D., Dor J., Kaufman B. et al. Cortical fibrosis and bloodvessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007;6(22):1626–33. doi: 10.1093/humrep/dem027
  20. Kuleva S.A., Kurochkina D.N., Zvyagintseva D.A. et al.
  21. Oncofertility in women cured of Hodgkin lymphoma in childhood. Meditsinskiy sovet = Medical Counsil 2019;6:176–83. (In Russ.).
  22. Wallace W.H., Thomson A.B., Kelsey T.W. The radiosensitivity of the human oocyte. Hum Reprod 2003;18(1):117–21. doi: 10.1093/humrep/deg016
  23. Pereyra Pacheco B., Méndez Ribas J.M., Milone G. et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81(3):391–7. doi: 10.1006/gyno.2001.6181
  24. Susuleva N.A., Valiev T.T., Martynova N.S., Mikhaylova S.N. Second tumors in children with hematological malignancies. Onkogematologiya = Oncohematology 2021;16(1):36–46. (In Russ.). doi: 10.17650/1818-8346-2021-16-1-36-46
  25. Friedmann D.L., Whitton J., Leisenring W. et al. Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102(14):1083–95. doi: 10.1093/jnci/djq238
  26. Swerdlow A.J., Barber J.A., Hudson G.V. et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498–509. doi: 10.1200/JCO.2000.18.3.498
  27. Van Leeuwen F.E., Klokman W.J., Veer M.B. et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18(3):487–97. doi: 10.1200/JCO.2000.18.3.487
  28. Bhatti P., Veiga L.H.S., Ronkers C.M. et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. Radiat Res 2010;174(6):741–52. doi: 10.1667/RR2240
  29. Travis L.B., Hill D.A., Dores G.M. et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290(4):465–75. doi: 10.1001/jama.290.4.465
  30. Travis L.B., Hill D.A., Dores G.M. et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97(19):1428–37. doi: 10.1093/jnci/dji290
  31. Aisenberg A.C., Finkelstein D.M., Doppke K.P. et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997;79(6):1203–10. doi: 10.1002/(sici)10970142(19970315)79:6<1203: aid-cncr20>3.0.co;2-2
  32. Conway J.L., Connors J.M., Tyldesley S. et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2017;97(1):35–41. doi: 10.1016/j.ijrobp.2016.10.004
  33. Aleksandrova E., Mihaylova I., Sergieva S. et al. Radiation-induced breast cancer in women with Hodgkinʼs disease. Rep Pract Oncol Radiother 2014;19(5):317–21. doi: 10.1016/j.rpor.2014.01.003
  34. Diller L., Nancarrow C.M., Shaffer K. et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2002;20(8):2085–91. doi: 10.1200/JCO.2002.08.031
  35. Valiev T.T., Pavlova T.Yu., Kovrigina A.M., Serebryakova I.N. Acute myeloid leukemia as second tumor in a patient with Burkitt’s lymphoma: literature review and a case report. Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(2):167–72. (In Russ.). doi: 10.21320/2500-2139-2021-14-2-167-172
  36. Zuna J., Cavé H., Eckert C. et al. Childhood secondary ALL after ALL treatment. Leukemia 2007;21(7):1431–5. doi: 10.1038/sj.leu.2404718
  37. Bhatia S., Robison L.L., Oberlin O. et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334(12):745–51. doi: 10.1056/NEJM199603213341201
  38. Hijiya N., Hudson M.M., Lensing S. et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007;297(11):1207–15. doi: 10.1001/jama.297.11.1207
  39. Kern W., Haferlach T., Schnittger S. et al. Prognosis in therapyrelated acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22(12):2510–11. doi: 10.1200/JCO.2004.99.301
  40. Morton L.M., Dores G.M., Curtis R.E. et al. Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 2013;31(27):3369–77. doi: 10.1200/JCO.2013.50.6832
  41. Jereczek-Fossa B.A., Alterio D., Jassem J. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30(4):369–84. doi: 10.1016/j.ctrv.2003.12.003
  42. Shafford E.A., Kingston J.E., Healy J.C. et al. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin’s disease. Br J Cancer 1999;80(5–6):808–14. doi: 10.1038/sj.bjc.6690425
  43. Vatutin N.T., Sklyannaya E.V., El-Khatib M.A., Taradin G.G. Cardiovascular complications of anticancer therapy: definition, etiology, epidemiology, pathogenesis, classification (part I). Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2017;22(6):345–50. (In Russ.). doi: 10.18821/1028-9984-2017-22-6-345-350
  44. Swerdlow A.J., Higgins C.D., Smith P. et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99(3):206–14. doi: 10.1093/jnci/djk029
  45. Lipshultz S.E., Lipsitz S.R., Mone S.M. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332(26):1738–43. doi: 10.1056/NEJM199506293322602
  46. Lipshultz S.E., Adams M.J., Colan S.D. et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013;128(17):1927–95. doi: 10.1161/CIR.0b013e3182a88099
  47. Van Nimwegen F.A., Schaapveld M., Janus C.P. et al. Сardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015;175(6):1007–17. doi: 10.1001/jamainternmed.2015.1180
  48. Cepelova M., Kruseova J., Luks A. et al. Accelerated atherosclerosis, hyperlipoproteinemia and insulin resistance in long-term survivors of Hodgkin lymphoma during childhood and adolescence. Neoplasma 2019;66(6):978–87. doi: 10.4149/neo_2019_190115N45
  49. Van Leeuwen F.E., Ng A.K. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program 2016;2016(1):323–30. doi: 10.1182/asheducation-2016.1.323

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.